NeurAxis, Inc. announced on June 10, 2025, that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been named as a recommended treatment option for Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This recommendation was published in the practice guidelines of the Journal of Pediatric Gastroenterology & Nutrition (JPGN).
NeurAxis's PENFS technology, utilized in its IB-Stim device, is the only FDA-cleared or approved treatment specifically recommended in these guidelines for pediatric patients. This inclusion provides strong clinical validation and is expected to enable momentum for large-scale insurance coverage for IB-Stim.
The CEO, Brian Carrico, highlighted this as a critical milestone, anticipating that the academic society guidelines recommendation will drive broad policy coverage and reimbursement. This development is expected to significantly improve patient access and incentivize broader adoption of IB-Stim across children's hospitals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.